Semaglutide (GLP-1) for Weight Loss
*NOT AVAILABLE to AL, AR, CA, MI, KS, ID
8 week protocol. (2 month supply)
This past June, the US Food and Drug Administration approved Semaglutide, a glucagon-like peptide 1 receptor agonist marketed as Wegovy, for chronic weight management based on results from the four 68-week STEP (Semaglutide Treatment Effect in People with obesity) trials. Now, the findings from a 2-year study presented at the Obesity Week conference in November suggest that the drug’s weight-loss benefits can be sustained.
Research has shown that at higher doses, Semaglutide could also prevent and treat diabetes, cardiovascular disease, ADDICTION and other related issues such as sleep apnea and osteoarthritis. The reasoning behind this is that patients are not only losing weight but also improving their health. It’s important to note that Semaglutide’s side effects are mild, and you might experience temporary symptoms such as diarrhea, nausea, vomiting, and constipation. These are very management symptoms and tend to occur during the beginning of the course of treatment.
Semaglutide, a GLP-1 receptor agonist, stimulates insulin release and suppresses glucagon, regulating blood sugar levels and promoting weight loss. People with a BMI of 27 kg/m2 or greater can experience improved glycemic control, reduced risk of complications like cardiovascular disease, and lose an average of 15% of their body weight. A once-weekly injection works by reducing appetite and increasing feelings of fullness, and should be used alongside a healthy diet and exercise.
Included in Price:
2 month supply of Semaglutide for beginners
All Physician Consults
Proprietary Optimization Software
Exclusive Membership Discounts